Home > Insider Trading > Filing (0001144204-19-044929)

Filing Details

Accession Number:: 0001144204-19-044929
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-09-17 17:04:28
Reporting Period:: 2019-09-17

Accepted Time:: 2019-09-17 17:04:28
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1692830	Satsuma Pharmaceuticals Inc.	STSA	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1315082	Ra Capital Healthcare Fund Lp	200 Berkeley Street, 18Th Floor Boston MA 02116	No	No	Yes	No
1346824	Ra Capital Management, Llc	200 Berkeley Street, 18Th Floor Boston MA 02116	Yes	No	Yes	No
1384859	Peter Kolchinsky	200 Berkeley Street, 18Th Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2019-09-17	2,008,409	$0.00	2,008,409	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-09-17	1,340,116	$0.00	3,348,525	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2019-09-17	1,333,333	$15.00	4,681,858	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2019-09-17	2,008,409	$0.00	2,008,409	$0.00
Common Stock	Series B Preferred Stock	Disposition	2019-09-17	1,340,116	$0.00	1,340,116	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

Reflects a 1-for-4.7 reverse stock split effective upon the effectiveness of the registration statement for the issuer's initial public offering.
Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into a share of the issuer's Common Stock, for no additional consideration, on a 1:1 basis at the consummation of issuer's initial public offering.
RA Capital Management, LLC (the "Adviser") is the general partner of the RA Capital Healthcare Fund, L.P.(the "Fund") and the investment adviser for an account owned by a separately managed account (the "Account"). Peter Kolchinsky is the sole manager of the Adviser. The Adviser and Dr. Kolchinsky may be deemed indirect beneficial owners of the securities and they disclaim beneficial ownership of the reported securities: (A) in reliance on Rule 16a-1(a)(1)(v) and (vii); and (B) held by the Fund, for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein.
The Adviser and Dr. Kolchinsky have no pecuniary interest in the reported securities held in the Account and disclaim: (A) beneficial ownership thereof for purposes of Rule 16a-1(a)(2); and (B) any obligation to file reports under Section 16 other than as a director by deputization. The filing of this Form 4 shall not be construed as an admission that either the Adviser or Dr. Kolchinsky is or was for the purposes of Section 16(a), or otherwise, the beneficial owner of any of the securities held in the Account.
Includes (a) 1,140,946 shares of Common Stock held by the Fund and (b) 192,387 held in the Account, in each case acquired in the issuer's initial public offering.
These securities include 3,923,460 shares held by the Fund and 758,398 shares held in the Account.
Represents 1,642,879 shares held by the Fund and 365,530 shares held in the Account.
Represents 1,139,635 shares held by the Fund and 200,481 shares held in the Account.